Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 14, 2016 - Issue 10
Submit an article Journal homepage
103
Views
4
CrossRef citations to date
0
Altmetric
Letter to the editor

Ticagrelor recommended over clopidogrel, only in clinical trials or also in a real-world practice?

Niccolò LombardiDepartment of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, Centre for Molecular Medicine (CIMMBA), University of Florence, Florence, Italy;Tuscan Regional Centre of Pharmacovigilance, Florence, ItalyCorrespondence[email protected]
View further author information
,
Giada CrescioliDepartment of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, Centre for Molecular Medicine (CIMMBA), University of Florence, Florence, Italy;Tuscan Regional Centre of Pharmacovigilance, Florence, ItalyView further author information
,
Alessandro MugelliDepartment of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, Centre for Molecular Medicine (CIMMBA), University of Florence, Florence, Italy;Tuscan Regional Centre of Pharmacovigilance, Florence, ItalyView further author information
&
Alfredo VannacciDepartment of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, Centre for Molecular Medicine (CIMMBA), University of Florence, Florence, Italy;Tuscan Regional Centre of Pharmacovigilance, Florence, ItalyView further author information
Pages 1103-1104 | Published online: 22 Aug 2016

References

  • Pappas C, Lekakis J, Alexopoulos D. Ticagrelor recommended over clopidogrel in STEMI patients. Expert Rev Cardiovasc Ther. 2016;1–3. [Epub ahead of print].
  • Harding SA, Van Gaal WJ, Schrale R, et al. Practical experience with ticagrelor: an Australian and New Zealand perspective. Curr Med Res Opin. 2015;31(8):1469–1477.
  • Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care. 2009;15(2 Suppl):S36–S41.
  • Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122(21):2131–2141.
  • Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care. 2015;4(6):555–560.
  • Unverdorben M, Parodi G, Pistolesi M, et al. Dyspnea related to reversibly-binding P2Y12 inhibitors: a review of the pathophysiology, clinical presentation and diagnostics. Int J Cardiol. 2016;202:167–173.
  • Sanchez-Galian MJ, Flores-Blanco PJ, Lopez-Cuenca A, et al. Ticagrelor related dyspnea in patients with acute coronary syndromes: incidence and implication on ticagrelor withdrawn. Int J Cardiol. 2015;187:517–518.
  • Gaubert M, Laine M, Richard T, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol. 2014;173(1):120–121.
  • Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038–1047.
  • Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56(3):185–193.
  • Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011;32(23):2945–2953.
  • Lombardi N, Lenti MC, Matucci R, et al. Ticagrelor-related dyspnea: an underestimated and poorly managed event? Int J Cardiol. 2015;179:238–239.
  • Subiakto I, Asrar ul Haq M, Van Gaal WJ. Bleeding risk and incidence in real world percutaneous coronary intervention patients with ticagrelor. Heart Lung Circ. 2015;24(4):404–406.
  • Sánchez-Galian MJ, Flores-Blanco PJ, López-Cuenca A, et al. Ticagrelor related dyspnea in patients with acute coronary syndromes: incidence and implication on ticagrelor withdrawn. Int J Cardiol. 2015;187:517–518.
  • Granger CB, Berger PB. Understanding the adverse effects of ticagrelor in practice. JAMA Cardiol. 2016;1:4.
  • McKee M, Britton A, Black N, et al. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ. 1999;319(7205):312–315.
  • Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med. 2000;342(25):1907–1909.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.